Status:
COMPLETED
Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hepatitis B
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
To evaluate the persistence of antibodies against hepatitis B, approximately 5 to 6 years after the first dose of the hepatitis B in the primary vaccination study.
Detailed Description
All subjects who participated in the primary vaccination study, where subjects who received GSK Biologicals' hepatitis B vaccine and who will consent to participate in this long-term follow-up study, ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Subjects should have participated in the primary study and should have received the first primary dose of vaccination more than five years ago and less than six years ago before blood sampling in this long-term follow-up study.
- Written informed consent obtained from the subject for the long-term follow-up.
Exclusion
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
632 Patients enrolled
Trial Details
Trial ID
NCT00329576
Start Date
May 1 2006
End Date
August 1 2006
Last Update
September 28 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Wilrijk, Belgium, 2610
2
GSK Investigational Site
Munich, Bavaria, Germany, 80799
3
GSK Investigational Site
Basel, Switzerland, 4002